A Study of ARRY-334543 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive a new
formulation of investigational study drug ARRY-334543. Patients will receive increasing doses
of study drug in order to achieve the highest dose possible that will not cause unacceptable
side effects. The patients will be followed to see what side effects and effectiveness the
study drug has, if any, in treating the cancer. In addition, the effect of food on the new
formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this
study (Active, not recruiting).
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer